Early use of disease-modifying drug treatments for relapsing-remitting MS can reduce the risk of conversion to secondary progressive MS, according to a study published in JAMA. The observational cohort study found fingolimod, alemtuzumab, or natalizumab were more effective in preventing progression than other disease-modifying treatments such as interferon beta and glatiramer acetate (HR 0.66). And ...
Already a member?
Enter your email to keep reading.